ArticleCureus2026
Human Herpes Virus 8 (HHV-8)-Associated Multicentric Castleman Disease in an HIV Patient With Severe Immunosuppression: A Diagnostic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human herpes virus 8 (HHV-8)-associated multicentric Castleman disease (HHV-8-MCD) is a rare lymphoproliferative disorder that predominantly affects individuals with advanced immunosuppression, especially people living with HIV. The clinical picture frequently overlaps with opportunistic infections, lymphoma, and haemophagocytic lymphohistiocytosis, creating significant diagnostic challenges. We present a case of a 51-year-old man recently diagnosed with HIV, who developed recurrent pyrexia, profound hyperferritinaemia, cytopenias, rapidly progressive lymphadenopathy, and escalating HHV-8 viraemia. Lymph node biopsy confirmed the diagnosis of HHV-8-positive MCD. Prompt initiation of rituximab and etoposide resulted in complete clinical and radiological remission. The case highlights the importance of rapid recognition, timely histological confirmation, early initiation of rituximab-based therapy, and multidisciplinary management in HHV-8-MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.